Search results for "TOTAL MESORECTAL EXCISION"

showing 10 items of 36 documents

Residual urine volume after total mesorectal excision: an indicator of pelvic autonomic nerve preservation? Results of a case-control study.

2004

Objective  The rate of bladder dysfunctions after total mesorectal excision (TME) for rectal cancer can be decreased by bilateral pelvic autonomic nerve preservation (PANP). However, it is not clear yet, how often partial nerve impairment may lead to bladder dysfunction. It was the aim of a case-control study, to examine the residual urine volume in patients before and after TME with and without complete PANP, in order to clarify, whether this parameter allows conclusions on the quality of PANP. Patients and methods  Regarding bladder function, a case group (n = 26) without complete PANP was compared with a control group (n = 26) with complete identification and nerve preservation according…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentUrinary systemRisk AssessmentPelvisAge DistributionPostoperative ComplicationsReference ValuesmedicineHumansAutonomic PathwaysProspective StudiesSex DistributionUrinary Bladder NeurogenicNeoadjuvant therapyNeurogenic bladder dysfunctionColectomyAgedProbabilityAged 80 and overAutonomic nervebusiness.industryRectal NeoplasmsIncidenceGastroenterologyCase-control studyOdds ratioMiddle Agedmedicine.diseaseUrination DisordersTotal mesorectal excisionSurgeryUrodynamicsQuartileCase-Control StudiesFemalebusinessFollow-Up StudiesColorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
researchProduct

EURECCA colorectal: multidisciplinary mission statement on better care for patients with colon and rectal cancer in Europe

2013

Contains fulltext : 125368.pdf (Publisher’s version ) (Closed access) BACKGROUND: Care for patients with colon and rectal cancer has improved in the last twenty years however still considerable variation exists in cancer management and outcome between European countries. Therefore, EURECCA, which is the acronym of European Registration of cancer care, is aiming at defining core treatment strategies and developing a European audit structure in order to improve the quality of care for all patients with colon and rectal cancer. In December 2012 the first multidisciplinary consensus conference about colon and rectum was held looking for multidisciplinary consensus. The expert panel consisted of…

Cancer ResearchDelphi TechniqueColorectal cancerDelphi methodPhysician's Practice PatternsGUIDELINESSTAGESurgical oncologyMinimal invasive surgeryTeams in the workplacePractice Patterns Physicians'Rectal cancerCooperative BehaviorSettore MED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIAddc:616Neoadjuvant radiotherapyMultidisciplinary teamTranslational research Tissue engineering and pathology [ONCOL 3]Total mesorectal excisionQuality assuranceColon cancerNeoadjuvant chemoradiotherapyEuropeColon cancer; Consensus; Delphi method; Minimal invasive surgery; Multidisciplinary team; Neoadjuvant chemoradiotherapy; Neoadjuvant radiotherapy; Quality assurance; Rectal cancerTreatment OutcomeOncologySURVIVALGuideline AdherenceColorectal NeoplasmsEuropaEUROCARECare of the sickCOUNTRIESmedicine.medical_specialtyMARGINEvidence-based practiceConsensusDelphi methodAuditDIAGNOSISSDG 3 - Good Health and Well-beingCàncer colorectalTreball en equipmedicineHumansCura dels malaltsPREOPERATIVE RADIOTHERAPYQuality of Health CarePatient Care Teambusiness.industryTOTAL MESORECTAL EXCISIONCancerAuditmedicine.diseaseColorectal cancerSurgeryOncology nursingFamily medicineREGISTRYInterdisciplinary Communicationbusiness
researchProduct

EURECCA colorectal: multidisciplinary management: European consensus conference colon & rectum.

2014

Contains fulltext : 137861.pdf (Publisher’s version ) (Closed access) BACKGROUND: Care for patients with colon and rectal cancer has improved in the last 20years; however considerable variation still exists in cancer management and outcome between European countries. Large variation is also apparent between national guidelines and patterns of cancer care in Europe. Therefore, EURECCA, which is the acronym of European Registration of Cancer Care, is aiming at defining core treatment strategies and developing a European audit structure in order to improve the quality of care for all patients with colon and rectal cancer. In December 2012, the first multidisciplinary consensus conference about…

Cancer ResearchQuality Assurance Health CareColorectal cancerCancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2]Delphi methodSurgical oncologyFAMILIAL ADENOMATOUS POLYPOSISTumours of the digestive tract Radboud Institute for Molecular Life Sciences [Radboudumc 14]MedicineSHORT-COURSE RADIOTHERAPYRectal cancerQuality assurance; Colon cancer; Rectal cancer; Multidisciplinary teams; Consensus; Delphi method; Audit; Neoadjuvant treatment; Adjuvant treatment; SurgerySettore MED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIADisease ManagementPHASE-III TRIALRANDOMIZED CONTROLLED-TRIALNeoadjuvant TherapyQuality assuranceColon cancerEuropemedicine.anatomical_structureTreatment OutcomeOncologyTRANSANAL ENDOSCOPIC MICROSURGERYColonic NeoplasmsPractice Guidelines as TopicHYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPYmedicine.medical_specialtyNeoadjuvant treatmentEvidence-based practiceConsensusLYMPH-NODE EVALUATIONDelphi methodRectumAuditSDG 3 - Good Health and Well-beingHumansCIRCUMFERENTIAL RESECTION MARGINddc:610business.industryRectal NeoplasmsTOTAL MESORECTAL EXCISIONCancerLONG-TERM SURVIVALAuditAdjuvant treatmentmedicine.diseaseSurgeryOncology nursingFamily medicineSurgeryMultidisciplinary teamsbusiness
researchProduct

Second St. Gallen European Organisation for Research and Treatment of Cancer Gastrointestinal Cancer Conference: consensus recommendations on controv…

2016

Contains fulltext : 171468pub.pdf (Publisher’s version ) (Open Access) Primary treatment of rectal cancer was the focus of the second St. Gallen European Organisation for Research and Treatment of Cancer (EORTC) Gastrointestinal Cancer Conference. In the context of the conference, a multidisciplinary international expert panel discussed and voted on controversial issues which could not be easily answered using published evidence. Main topics included optimal pretherapeutic imaging, indication and type of neoadjuvant treatment, and the treatment strategies in advanced tumours. Here we report the key recommendations and summarise the related evidence. The treatment strategy for localised rect…

Cancer ResearchStagingColorectal cancermedicine.medical_treatmentNeoplasias Gastrointestinais030230 surgerySYNCHRONOUS LIVER METASTASESImagingCOLORECTAL-CANCER0302 clinical medicineADJUVANT CHEMOTHERAPYTumours of the digestive tract Radboud Institute for Molecular Life Sciences [Radboudumc 14]SHORT-COURSE RADIOTHERAPYRectal cancerNeoadjuvant therapyGastrointestinal NeoplasmsRectal Neoplasms/drug therapyCombination chemotherapyChemoradiotherapyCombined Modality TherapyTotal mesorectal excisionNeoadjuvant TherapyEuropeNeoplasias do Recto/quimioterapiaOncology030220 oncology & carcinogenesisMEDIAN FOLLOW-UPLife Sciences & BiomedicineDiagnostic Imagingmedicine.medical_specialtyAntineoplastic AgentsLOCAL RECURRENCERisk AssessmentCOURSE PREOPERATIVE RADIOTHERAPY03 medical and health sciencesmedicineHumansGastrointestinal cancerOncology & CarcinogenesisRadiochemotherapyNeoplasm StagingScience & TechnologyRadiotherapyRectal Neoplasmsbusiness.industryGeneral surgeryTOTAL MESORECTAL EXCISIONCancerRANDOMIZED PHASE-IIImedicine.diseaseSurgeryRadiation therapySurgerybusiness1112 Oncology And CarcinogenesisChemoradiotherapyPOSTOPERATIVE CHEMORADIOTHERAPY
researchProduct

Short- and Long-Term Quality of Life and Bowel Function in Patients With MRI-Defined, High-Risk, Locally Advanced Rectal Cancer Treated With an Inten…

2015

Objective Intensified preoperative treatments have been increasingly investigated in locally advanced rectal cancer (LARC), but limited data are available for the impact of these regimens on quality of life (QoL) and bowel function (BF). We assessed these outcome measures in EXPERT-C, a randomized phase 2 trial of neoadjuvant capecitabine combined with oxaliplatin (CAPOX), followed by chemoradiation therapy (CRT), total mesorectal excision, and adjuvant CAPOX with or without cetuximab in magnetic resonance imaging-defined, high-risk LARC. Methods and Materials QoL was assessed using the European Organization for Research and Treatment of Cancer QLQ-C30 and QLQ-CR29 questionnaires. Bowel inc…

Cancer Researchmedicine.medical_specialtyOrganoplatinum CompoundsColorectal cancerHealth StatusCetuximabAntineoplastic AgentsUrinary incontinenceBowel incontinenceSeverity of Illness Indexlaw.inventionRandomized controlled trialQuality of lifelawSurveys and QuestionnairesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansFecal incontinenceRadiology Nuclear Medicine and imagingSexual Dysfunctions PsychologicalCapecitabineRadiationRectal Neoplasmsbusiness.industryRectumChemoradiotherapy Adjuvantmedicine.diseaseMagnetic Resonance ImagingTotal mesorectal excisionNeoadjuvant TherapyhumanitiesSurgeryOxaliplatinOncologyChemotherapy AdjuvantQuality of Lifemedicine.symptombusinessFecal IncontinenceChemoradiotherapyInternational Journal of Radiation Oncology*Biology*Physics
researchProduct

Transanale totale mesorektale Exzision – Voraussetzungen zur sicheren Implementierung

2019

ZusammenfassungDie transanale totale mesorektale Exzision (TaTME) ist eine innovative und technisch anspruchsvolle Methode zur chirurgischen Behandlung des Rektumkarzinoms. Ziel dieses Artikels ist es, die Voraussetzungen und Trainingsbedingungen darzustellen, die für die sichere Implementierung dieses komplexen Verfahrens entscheidend sind. Die internationalen Expertenmeinungen werden vor dem Hintergrund der veröffentlichten Ergebnisse aus TaTME-Schulungszentren diskutiert. Darüber hinaus werden eigene Erfahrungen aus den TaTME-Anatomiekursen (Video) und einer ersten klinischen Serie von 102 TaTMEs mitgeteilt. Das Verfahren sollte in erster Linie von kolorektal spezialisierten Fachärzten f…

Gynecology03 medical and health sciencesmedicine.medical_specialty0302 clinical medicinebusiness.industry030220 oncology & carcinogenesismedicine030211 gastroenterology & hepatologySurgerybusinessTotal mesorectal excisionZentralblatt für Chirurgie - Zeitschrift für Allgemeine, Viszeral-, Thorax- und Gefäßchirurgie
researchProduct

Robotic transanal total mesorectal excision: Is the future now?

2021

Total mesorectal excision (TME) is the standard surgical treatment for the curative radical resection of rectal cancers. Minimally invasive TME has been gaining ground favored by the continuous technological advancements. New procedures, such as transanal TME (TaTME), have been introduced to overcome some technical limitations, especially in low rectal tumors, obese patients, and/or narrow pelvis. The earliest TaTME reports showed promising results when compared with the conventional laparoscopic TME. However, recent publications raised concerns regarding the high rates of anastomotic leaks or local recurrences observed in national series. Robotic TaTME (R-TaTME) has been proposed as a nove…

High ratemedicine.medical_specialtyMinimally-invasive surgerybusiness.industryMinireviewsRoboticsRectal TumorsTransanal approachTotal mesorectal excisionSurgeryNatural orifice surgeryDissectionAnastomotic leaksmedicineNarrow pelvisRectal cancerSurgical treatmentRadical resectionbusinessTotal mesorectal excisionWorld Journal of Gastrointestinal Surgery
researchProduct

The 2017 Assisi Think Tank Meeting on rectal cancer: A positioning paper

2019

BACKGROUND AND PURPOSES: To describe current practice in the management of rectal cancer, to identify uncertainties that usually arise in the multidisciplinary team (MDT)'s discussions ('grey zones') and propose next generation studies which may provide answers to them. MATERIALS AND METHODS: A questionnaire on the areas of controversy in managing T2, T3 and T4 rectal cancer was drawn up and distributed to the Rectal-Assisi Think Tank Meeting (ATTM) Expert European Board. Less than 70% agreement on a treatment option was indicated as uncertainty and selected as a 'grey zone'. Topics with large disagreement were selected by the task force group for discussion at the Rectal-ATTM. RESULTS: The…

MaleBest practice guidelinesColorectal cancermedicine.medical_treatmentSettore MED/18 - CHIRURGIA GENERALEMedical Oncology030218 nuclear medicine & medical imagingCOLORECTAL-CANCER0302 clinical medicineADJUVANT CHEMOTHERAPYRectal cancerNeoadjuvant therapyRandomized Controlled Trials as TopicSettore MED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIARadiology Nuclear Medicine & Medical ImagingChemoradiotherapyCytoreduction Surgical ProceduresHematologyMiddle AgedOPEN-LABELTotal mesorectal excisionNeoadjuvant TherapyOncology030220 oncology & carcinogenesisFemaleLife Sciences & Biomedicinemedicine.medical_specialtyOrgan preservationLOCAL RECURRENCEAreas of uncertaintiesCOURSE PREOPERATIVE RADIOTHERAPYAreas of uncertainties; Best practice guidelines; Colorectal cancer; Organ preservation; Personalized medicine;03 medical and health sciencesLow rectal cancerRADIATION-THERAPYmedicineHumansRadiology Nuclear Medicine and imagingMedical physicsEXTRAMURAL VASCULAR INVASIONNeoplasm StagingScience & TechnologyRectal Neoplasmsbusiness.industryTask forceAreas of uncertainties; Best practice guidelines; Colorectal cancer; Organ preservation; Personalized medicineTOTAL MESORECTAL EXCISIONRANDOMIZED PHASE-IIINEOADJUVANT CHEMORADIOTHERAPYmedicine.diseaseColorectal cancerPersonalized medicineClinical trialRadiation therapyPersonalized medicinebusiness
researchProduct

Comparison between MRI and pathology in the assessment of tumour regression grade in rectal cancer

2017

Background: Limited data exist regarding the correlation between MRI tumour regression grade (mrTRG) and pathological TRG (pTRG) in rectal cancer. Methods: mrTRG and pTRG were compared in rectal cancer patients from two phase II trials (EXPERT and EXPERT-C). The agreement between radiologist and pathologist was assessed with the weighted κ test while the Kaplan–Meier method was used to estimate survival outcomes. Results: One hundred ninety-one patients were included. Median time from completion of neoadjuvant treatment to pre-operative MRI and surgery was 4.1 weeks (interquartile range (IQR): 3.7–4.7) and 6.6 weeks (IQR: 5.9–7.6), respectively. Fair agreement was found between mrTRG and pT…

MaleCancer ResearchPathologySURGERYColorectal cancerACCURACYmedicine.medical_treatmentMagnetic resonance tumour regression gradePREOPERATIVE CHEMORADIATIONKaplan-Meier EstimateTHERAPY030218 nuclear medicine & medical imaging0302 clinical medicineInterquartile rangeRectal cancerNeoadjuvant therapyAged 80 and overCOMPLETE RESPONSEmedicine.diagnostic_testMiddle AgedMagnetic Resonance ImagingNeoadjuvant TherapyOncology030220 oncology & carcinogenesisFemaleRadiologyLife Sciences & BiomedicineRADIOTHERAPYAdultmedicine.medical_specialtyCytodiagnosismagnetic resonance tumour regression gradeDisease-Free Survival03 medical and health sciencesClinical Trials Phase II as TopicmedicinePathological tumour regression gradeHumansOncology & Carcinogenesisrectal cancerPathologicalpathological tumour regression gradeAgedNeoplasm StagingScience & TechnologyRectal Neoplasmsbusiness.industryTOTAL MESORECTAL EXCISIONMagnetic resonance imagingChemoradiotherapy AdjuvantRANDOMIZED PHASE-IIINEOADJUVANT CHEMORADIOTHERAPYmedicine.diseaseClinical trialRadiation therapyClinical StudyFOLLOW-UPbusiness1112 Oncology And CarcinogenesisChemoradiotherapy
researchProduct

An international multicentre prospective audit of elective rectal cancer surgery; operative approach versus outcome, including transanal total mesore…

2018

Introduction: Transanal total mesorectal excision (TaTME) has rapidly emerged as a novel approach for rectal cancer surgery. Safety profiles are still emerging and more comparative data is urgently needed. This study aimed to compare indications and short-term outcomes of TaTME, open, laparoscopic, and robotic TME internationally. Methods: A pre-planned analysis of the European Society of Coloproctology (ESCP) 2017 audit was performed. Patients undergoing elective total mesorectal excision (TME) for malignancy between 1 January 2017 and 15 March 2017 by any operative approach were included. The primary outcome measure was anastomotic leak. Results: Of 2579 included patients, 76.2% (1966/257…

MaleLaparoscopic surgerymedicine.medical_specialtyColorectal cancermedicine.medical_treatmentOperative TimeAnastomosisMalignancyrectal cancer ; laparoscopic surgery ; TME ; transanal TME ; TaTME ; robotic surgery ; randomized clinical-trial ; short-term outcomes ; laparoscopic-assisted resection ; pathological outcomes ; anastomotic leakage ; initial-experience ; riskNO03 medical and health sciencesPostoperative Complications0302 clinical medicineRobotic Surgical Proceduresrobotic surgerytransanal TMEHumansMedicineRobotic surgeryProspective Studieslaparoscopic surgery; Rectal cancer; robotic surgery; TaTME; TME; transanal TME; GastroenterologyRectal cancerAgedTransanal Endoscopic Surgeryta3126Medical AuditUnivariate analysisProctectomyRectal Neoplasmsbusiness.industryRectumGastroenterologyTMEMargins of ExcisionMiddle Agedmedicine.diseaseTotal mesorectal excisionTaTMElaparoscopic surgerySurgeryTreatment OutcomeElective Surgical Procedures030220 oncology & carcinogenesisRectal cancer surgeryFemaleLaparoscopy030211 gastroenterology & hepatologybusiness
researchProduct